Author(s): Tapas Kumar Mohapatra, Bharat Bhusan Subudhi

Email(s): bharatbhusans@gmail.com

DOI: 10.5958/0974-360X.2019.00337.8   

Address: Tapas Kumar Mohapatra, Bharat Bhusan Subudhi*
Drug Development and Analysis Laboratory, School of Pharmaceutical Sciences, Siksha O Anusandhan (Deemed to be University), Bhubaneswar
*Corresponding Author

Published In:   Volume - 12,      Issue - 4,     Year - 2019


ABSTRACT:
Repurposing refers to the study of drugs which is already approved to treat one disease for the treatment of other diseases. Aspirin (ASA) is widely used for the treatment of pain, fever or inflammation. It has been repurposed against cardiovascular disorders. In recent years ASA has generated a significant interest for prevention of cancer, central nervous system disorder, diabetes and cryptococcal infection due to its influence on COX dependent and COX independent mechanism. Following oral administration ASA is rapidly hydrolyzed to salicylic acid (SA). Since SA has selective ability to inhibit COX-2, its application for repurposing is limited. Besides, ASA is more potent due to its capacity for irreversible inhibition of COX. Thus for repurposing it is desirable to ensure adequate availability of ASA at site of action. This is a challenge as issues related to solubility, stability and toxicity needs to be simultaneously addressed while repurposing.


Cite this article:
Tapas Kumar Mohapatra, Bharat Bhusan Subudhi. Repurposing of Aspirin: Opportunities and Challenges. Research J. Pharm. and Tech. 2019; 12(4):2037-2044. doi: 10.5958/0974-360X.2019.00337.8

Cite(Electronic):
Tapas Kumar Mohapatra, Bharat Bhusan Subudhi. Repurposing of Aspirin: Opportunities and Challenges. Research J. Pharm. and Tech. 2019; 12(4):2037-2044. doi: 10.5958/0974-360X.2019.00337.8   Available on: https://rjptonline.org/AbstractView.aspx?PID=2019-12-4-93


Recomonded Articles:

Research Journal of Pharmacy and Technology (RJPT) is an international, peer-reviewed, multidisciplinary journal.... Read more >>>

RNI: CHHENG00387/33/1/2008-TC                     
DOI: 10.5958/0974-360X 

0.38
2018CiteScore
 
56th percentile
Powered by  Scopus


SCImago Journal & Country Rank


Recent Articles




Tags


Not Available